IP Library Granted Patent US 8,211,916
Granted Patent B2
US 8,211,916 · App. 12/018,172 · Granted Jul 3, 2012

N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith

Assignee: Wayne State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,211,916
App. No.
12/018,172
Granted
Jul 3, 2012
Kind
B2
Abstract

N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl] piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). The compounds have utility in treating CNS disorders, including but not limited to cocaine addiction, depression, and Parkinson's disease.

Claims (33)

1. A compound having formula:

wherein:

Z 1 is —NH 2 , —OH, ═O, Oalkyl, —Oaryl, or —O—C(O)—R 5 ;

w is a number representing that one or more hydrogen atoms of one or more methylene groups are replaced by Z 1 ;

A is

X is selected from the group consisting of —NH—, —NR 4 , and —O—;

R 4 is C 1-4 alkyl, NH 2 , C 1-4 hydroxyalkyl, halogenated C 1-4 alkyl, C 2-4 alkenyl, C 2-4 hydroxyalkenyl, halogenated C 2-4 alkenyl, C 2-4 and alkynyl, or C 2-4 halogenated alkynyl;

Y is —H, —NH 2 , —OH, ═O, or —O—C(O)—R 5 ;

1 is 0, 1, or 2;

n is 1 or 2;

m is 1, 2, 3 or 4;

o is 0, 1, 2, 3, or 4;

p is 0, 1, 2, 3, or 4;

q is 0, 1, 2, or 3;

R, R 1 , and R 2 are selected from the group consisting of H, F, Cl, Br, I, CN, COOEt, OH, NO 2 , NH 2 , OR 5 , wherein R 5 is C 1-18 alkyl, C 5-6 cycloalkyl, or C 2-8 alkenyl or R 2 is a 5 or 6 membered heterocycle;

and where one or more CH 2 , groups of (CH 2 ) m are optionally substituted by CR 7 R′ 7 ;

R 7 is H, —OR 11 , or NR 11 ;

R′ 7 is H, —C 1-8 alkyl or R 7 , R′ 7 are combined together as ═O;

R 11 is H, C 1-8 alkyl, C 2-8 alkylene, C 6-8 alkyl-aryl, or —COOR 12 ; and

R 12 is C 1-8 alkyl, C 2-8 alkylene, OR C 6-18 alkyl-aryl;

or a pharmaceutically acceptable salt or derivative thereof.

2. The compound of claim 1 having the formula:

3. The compound of claim 1 wherein Z 1 is H.

4. The compound of claim 1 wherein Z 1 is OH.

5. The compound of claim 1 wherein m is 2.

6. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

7. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 24, 2012
From: WAYNE STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028621/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2009
From: DUTTA, ALOKE K.
To: WAYNE STATE UNIVERSITY
Reel/Frame 022155/0138 →
Continuity (5)
Continuation In Part 11007484 · Dec 8, 2004
Continuation 10311796 · Mar 28, 2003
Continuation PCTUS0140964 · Jun 14, 2001
Provisional Application 60212921 · Jun 20, 2000
Related Publication 20080182991A1 · Jul 31, 2008